⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308213 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL27857854 | 0.97 | — | — | |
| SCHEMBL3970325 | 0.92 | — | — | |
| SCHEMBL20334775 | 0.92 | — | — | |
| SCHEMBL3469054 | 0.90 | HIF1A (0.46) | — | |
| SCHEMBL2500151 | 0.79 | — | — | |
| SCHEMBL447351 | 0.79 | — | — | |
| SCHEMBL21022704 | 0.79 | — | — | |
| SCHEMBL21090095 | 0.79 | HIF1A (0.38) | — | |
| SCHEMBL18735919 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112451460-A | Extraction method of crocus sativus extract and stretch mark removing cream containing extract | 广州市医康生物科技有限公司 | 2021-03-09 | — | — | CN | claimed |
| US-11944687-B2 | Carbohydrate conjugate RNA agents and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-4253395-A2 | PROCESSES FOR THE PREPARATION OF CARBOHYDRATE CONJUGATED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-2879718-B1 | PROCESSES FOR THE PREPARATION OF CARBOHYDRATE CONJUGATED RNA AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-04-25 | — | — | US | disclosed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220348920-A1 | LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2022-11-03 | — | — | US | disclosed |
| US-20220315924-A1 | LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2022-10-06 | — | — | US | disclosed |
| US-11459561-B2 | IncRNAS for therapy and diagnosis of angiogenesis | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2022-10-04 | — | — | US | disclosed |
| US-11371043-B2 | LncRNAs for therapy and diagnosis of cardiac hypertrophy | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2022-06-28 | — | — | US | disclosed |
| WO-2008094860-A2 | TREATING OCULAR DISEASES USING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA ANTAGONISTS | ALLERGAN, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20070088040-A1 | Antibacterial compounds | ABBVIE INC. | 2007-04-19 | — | — | US | disclosed |
| EP-1735009-A2 | iRNA AGENTS TARGETING VEGF | Alnylam Pharmaceuticals Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060223770-A1 | IRNA agents targeting VEGF | ALNYLAM EUROPE AG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20060094032-A1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| WO-2005089224-A2 | iRNA AGENTS TARGETING VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-5036153-A | Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates | PFIZER INC., A CORP. OF DE | 1991-07-30 | — | — | US | disclosed |
| EP-0420487-A2 | Process for optically active 2-alkyl-2,5-diazabicyclo[2.2.1]heptanes | PFIZER INC. (US) | 1991-04-03 | — | — | EP | disclosed |
| EP-0397351-A1 | Preparation of diazabicyclic intermediates | PFIZER INC. (US) | 1990-11-14 | — | — | EP | disclosed |